Year: 2026

Categories : Metabolic DisordersTags :

Researchers Quantify How Much Obesity Reduction Prevents Common Conditions

On By ModernMedia
Source: Pixabay CC0

A University of Exeter-led study has quantified the role of obesity in common long-term conditions, showing for the first time the effect of losing weight in preventing multiple diseases.  

Conditions that often occur together may share an underlying cause, which can be key to prevention or treatment. The picture of which conditions co-occur is complex, so researchers paired them together, to allow them to identify shared causes more simply. The study found that obesity is the main shared cause between ten pairs of commonly occurring conditions.   

The research specifically measured how much weight reduction would reduce the risk of the next diagnosis.  In the largest study of its kind, published in Communications Medicine – Nature, the team studied 71 conditions which often occur together, such as type 2 diabetes and osteoarthritis, or kidney disease and chronic obstructive pulmonary disease (COPD).  

The GEMINI study, funded by the UKRI Medical Research Council and supported by the National Institute for Health and Care Research (NIHR), used genetics and healthcare data drawn from a number of large datasets internationally. They found that obesity was part of the cause for  61 of the 71 conditions. They also found that obesity explained all of the genetic overlap in ten pairs of conditions, suggesting it is the main driver for why they frequently occur together.  

Body mass index, or BMI, is a scaled measure of weight – a number over 30 units indicates obesity, while less than 25 indicates “normal” weight. The study quantified how much a reduction in BMI would reduce the risk of both conditions at a population level for people overweight or living with obesity. For example, for every thousand people who have both chronic kidney disease and osteoarthritis, a BMI reduction of 4.5 units would have prevented 17 of them developing both conditions or nine people per thousand with type 2 diabetes and osteoarthritis.  

The team also established the pairs of conditions where obesity is not the main cause and are now investigating other mechanisms.  

Study lead Professor Jack Bowden, at the University of Exeter Medical School: “We’ve long known that certain diseases often occur together, and also that obesity increases the risk of many diseases. This largescale study is the first to use genetics to quantify the role of obesity in causing diseases to occur in the same individuals. We found that for some disease pairings, obesity is the major driving force. Our research provides much more detail about the links between obesity and disease, which will help clinicians target specific advice to patients going forward.”  

Study author Professor Jane Masoli, of the University of Exeter Medical School, who is a Consultant Geriatrician and regional NIHR Ageing lead, said: “Currently nine million people in the UK live with two or more long-term conditions.  Understanding how to prevent diseases accumulating is a key national research and healthcare priority.  This study further strengthens the case to tackle obesity through public health programmes, reinforcing the importance of lifelong obesity management in the NHS strategy on prevention. Our work shows that this could reduce the risk of accumulating multiple health conditions, supporting people to live longer, healthier lives.”  

This research represents another important publication from the GEMINI (Genetic Evaluation of Multimorbidity towards INdividualisation of Interventions) collaborative. Led by the University of Exeter, GEMINI includes people with multimorbidity, health care professionals including those in primary care and experts in statistics and genetics, and was one of six programmes funded by the UKRI strategic priorities fund, an £830 million investment in multimorbidity research. 

The GEMINI team are working to further understand why some conditions more frequently co-occur in the same patients. The team are quantifying the role of other, known modifiable risk factors beyond obesity, and are finding novel genes and pathways that could point to new ways to intervene and improve health. GEMINI data, results, and code are free to download (https://github.com/GEMINI-multimorbidity), and the pairwise genetic and observational correlations can be viewed interactively (https://gemini-multimorbidity.shinyapps.io/atlas/).   

By Louise Vennells

Source: University of Exeter

Categories : Obstetrics & GynaecologyTags :

Research Links High Doses of Antioxidants to Offspring Birth Defects

On By ModernMedia
Photo by Nataliya Vaitkevich

Antioxidants have been marketed as miracle supplements, touted for preventing chronic diseases and cancers; treating COPD and dementia; and slowing aging. While antioxidant therapies are widely used to treat male infertility, a new study from the Texas A&M College of Veterinary Medicine and Biomedical Sciences (VMBS) found that regularly consuming high doses of antioxidants negatively influences sperm DNA and may lead to offspring born with differences in craniofacial development.

In a study, published in the journal Frontiers in Cell and Developmental Biology, a team of researchers led by Dr Michael Golding examined the effects of N-acetyl-L-cysteine (NAC) and selenium (Se) – two widely used antioxidants – in mouse models.

They found that offspring of male mice exposed to antioxidants for six weeks exhibited skull and facial shape differences, even while the father’s health didn’t change.

These findings suggest that men should exercise caution when consuming high doses of antioxidants, especially if they’re planning to have children in the near future.   

When good goes too far

Antioxidants like NAC — which is a key ingredient in many nutritional supplements, including multivitamins — are often used to treat oxidative stress, which can be caused by excessive alcohol consumption.

Because Golding’s lab has been studying the effects of parental alcohol consumption on offspring – and has successfully correlated this consumption to a whole host of issues in children born to males who consumed excessive amounts of alcohol, including craniofacial abnormalities – his team was interested in the impacts of adding NAC or Se to a male mouse’s diet.

“We know alcohol causes oxidative stress and we were looking to push back on it by adding a supplement known to lower oxidative stress,” said Golding, a professor in the VMBS’ Department of Veterinary Physiology and Pharmacology. “When we realised that offspring born to males that had only been given NAC were displaying skull and facial differences, it was a surprise because this molecule is universally thought to be good.

“When we sat down to think it through, we realised that it makes sense – you take a multivitamin to ensure that you’re in balance, but if the thing that you’re taking to ensure you’re in balance is unbalanced (the dose of antioxidants is too high), then you’re not doing a good thing.”

It is well established that high doses of antioxidants can have negative impacts; research has proven that antioxidants can diminish the effects of exercise in endurance athletes, for example, and, in the case of professional athletes, can lead to negative outcomes in performance metrics.

“Sperm health is another performance metric; it’s just not one that we think about in everyday life,” Golding said. “If you’re taking a high dose antioxidant, you could be diminishing your reproductive fitness and part of the journey toward the bad outcome is going to be the effects on the offspring.”

What the face reveals about the brain

Among their unanticipated findings was that female offspring, in particular, exhibited significantly closer-set eyes and smaller skulls, which are also symptoms of foetal alcohol syndrome.

“There’s a very commonly accepted truism in paediatric medicine that the face mirrors the brain, because the brain and the face form at the same time,” Golding said. “When your face migrates (during gestation), it’s using cues from your brain to know where to go, and if the two things are not aligned, there’s either a delay or some kind of abnormality in brain development.

“So, if you see abnormalities in the midline of the face, you’re probably going to see midline abnormalities in the brain,” he said. “People with these abnormalities typically have problems with impulse control, neurological conditions like epilepsy, and other developmental issues.”

Whether the offspring in this project will exhibit central nervous system dysfunction will require further study.

The dose makes the difference

While the lab continues to research this “unexplored frontier,” Golding says in the case of antioxidants, too much of a good thing can, in fact, be too much, especially in the absence of a medical reason to take an antioxidant supplement.

Because many men regularly take high doses of these supplements – including products that contain antioxidant-rich ingredients – it’s important to pay attention to how much of these compounds are listed on the label. This includes NAC, which is one of the key ingredients in many multivitamins and is often found in high doses in these pills.

“The larger message here is that there’s a balance,” Golding said. “Think of yourself as a plant — if you stick your plant out in the sun too long, it’s going to get dehydrated. If you overwater your plant, it gets root rot. But if you have the right balance of sunshine and water, that’s when growth occurs. Health is in that domain.

“If your vitamins are providing 1,000% of the recommended daily amount, you should be cautious,” he said. “If you stick to the 100% range, then you should be OK.”

Categories : Emergency MedicineTags :

Potential New Treatment for Sepsis Shows Promise in Trial

On By ModernMedia

Griffith University researchers may have unlocked the secret to treating sepsis, with a Phase II clinical trial in China successfully concluding with promising results.

Photo by Alex Fedini on Pixabay

Griffith University researchers may have unlocked the secret to treating sepsis, with a Phase II clinical trial in China successfully concluding with promising results. The sepsis drug candidate, a carbohydrate-based drug called STC3141, was co-developed by Distinguished Professor Mark von Itzstein AO and his team from Griffith’s Institute for Biomedicine and Glycomics, and Professor Christopher Parish and his team at The Australian National University.

“The trial met the key endpoints to indicate the drug candidate was successful in reducing sepsis in humans,” Professor von Itzstein said.

STC3141 was administered as an infusion via a cannula and counteracted a significant biological molecule release phenomenon which occurred in the body during the course of sepsis.

The small-molecule experimental drug was a carbohydrate-based molecule and could treat sepsis by reversing organ damage.

Sepsis was known to affect millions of hospitalised patients across the world each year and occurred when the body’s immune response to an infection attacked and injured its own tissues and organs.

“When sepsis is not recognised early and managed promptly, it can lead to septic shock, multiple organ failure and death,” Distinguished Professor von Itzstein said.

The trial, conducted by Grand Pharmaceutical Group Limited (Grand Pharma), involved 180 patients with sepsis, one of the leading causes of death and long-term disability worldwide.

Currently, there is no specific anti-sepsis therapy available, and sepsis is considered a clinical unmet need.

Professor von Itzstein said Grand Pharma would now look to progress to a Phase III trial to continue testing the efficacy of the novel treatment.

“It’s hoped we could see the treatment reach the market in a handful years, potentially saving millions of lives,” he said.

Executive Director of the Institute for Biomedicine and Glycomics, Professor Paul Clarke, said: “I am thrilled to see the results of the trial which ultimately aims to save lives.”

“The Institute and its researchers collectively work on translational research to deliver real and immediate impacts both in Australia, and globally to transform lives.”

Source: Griffith University

Categories : CancerTags :

Strong Evidence for Effectiveness of Metastasis-directed Radiotherapy in Prostate Cancer

On By ModernMedia
Photo by Jo McNamara

Metastasis-directed therapy (MDT) significantly improved outcomes in patients with oligometastatic prostate cancer, according to a new study from researchers at The University of Texas MD Anderson Cancer Center published today in Lancet Oncology.

The study is a first-of-its-kind meta-analysis of individual patients across all available randomised clinical trials evaluating the addition of metastasis-directed radiation therapy to standard-of-care treatment.

According to corresponding author Chad Tang, MD, associate professor of Genitourinary Radiation Oncology, gathering level one evidence of the benefits of MDT in this cancer type has been a challenge due to several factors. Most significant among them are that only a small number of patients have oligometastatic cancer – meaning they have multiple metastases but not enough to be considered widely metastatic – and the relative indolence of oligometastatic disease.

“If we can identify and treat this disease in the narrow window before it spreads too far, we know that patient outcomes are significantly better. But gathering this data is difficult,” Tang said. “By bringing together all available patient data from randomized clinical trials, we have provided the best evidence to date that MDT improves patient outcomes.”

What is MDT and what is the significance of this study on oligometastatic prostate cancer?

Broadly, MDT can include multiple treatment approaches. In this setting, the most common form of MDT is radiation therapy, which targets metastases at a stage when cancer has begun to spread but hasn’t yet spread widely. This approach potentially brings several benefits to patients, such as delaying the time to progression and limiting the need for more aggressive therapies that will further impact quality of life.

The most common form of MDT is stereotactic body radiation therapy (SBRT), a type of very precise radiation therapy. In previous studies, like the Phase II EXTEND trial presented in 2024, MDT significantly improved progression-free survival (PFS). 

These and similar findings have led to widespread adoption of MDT in the oligometastatic setting, despite the lack of level one evidence.

To try and address that lack of data, researchers from several institutions created a global consortium, known as X-MET, to gather the data from all randomized trials for analysis at MD Anderson. Individual patient data from seven trials were ultimately included in this meta-analysis, known as WOLVERINE.

What were the results of the study?

This study, which included 574 men, showed a significant benefit for the patients receiving the MDT arm in PFS, radiographic PFS, and castration resistance-free survival.

Patients in the MDT arm gained a median of 7.6 months before disease progression, 4.9 months before radiographic disease progression, and 2.5 months before developing castration-resistance disease, compared to patients receiving standard of care alone. These findings were consistent across the individual trials and in the aggregated data.

Additionally, there were no significant differences in safety between the treatment arms. No grade five toxicities were observed in either arm, and any adverse effects above grade two were similar between the two arms.

“We hope that this dataset will lay the groundwork for future Phase III trials, which hopefully will show an overall survival benefit for these patients,” Tang said. “However, what this data does already show is the best evidence to date that MDT significantly benefits patients without adding any notable safety risks.”

Source: The University of Texas MD Anderson Cancer Center

Categories : Cancer IT in HealthcareTags :

AI Treatment Advice Diverges with Physicians’ in Late Stage HCC

On By ModernMedia

LLMs tended to prioritise tumour-related factors whereas physicians prioritise liver function when providing treatment recommendations

Photo by National Cancer Institute on Unsplash

Large language models (LLM) can generate treatment recommendations for straightforward cases of hepatocellular carcinoma (HCC) that align with clinical guidelines but fall short in more complex cases, according to a new study by Ji Won Han from The Catholic University of Korea and colleagues published January 13th in the open-access journal PLOS Medicine.

Choosing the most appropriate treatment for patients with liver cancer is complicated. While international treatment guidelines provide recommendations, clinicians must tailor their treatment choice based on cancer stage and liver function as well as other factors such as comorbidities.

To assess whether LLMs can provide treatment recommendations for hepatocellular carcinoma (HCC) that reflect real-world clinical practice, researchers compared suggestions generated by three LLMs (ChatGPT, Gemini, and Claude) with actual treatments received by more than 13,000 newly diagnosed patients with HCC in South Korea.

They found that, in patients with early-stage HCC, higher agreement between LLM recommendations and actual treatments was associated with improved survival. The inverse was seen in patients with advanced-stage disease. Higher agreement between LLM treatment recommendations and actual practice was associated with worse survival. LLMs placed greater emphasis on tumor factors, such as tumor size and number of tumors, while physicians prioritized liver function.

Overall, the findings suggest that LLMs may help to support straightforward treatment decisions, particularly in early-stage disease, but are not presently suitable for guiding care decisions for more complex cases that require nuanced clinical judgment. Regardless of stage, LLM advice should be used with caution and considered as a supplement to clinical expertise.

The authors add, “Our study shows that large language models can help support treatment decisions for early-stage liver cancer, but their performance is more limited in advanced disease. This highlights the importance of using LLMs as a complement to, rather than a replacement for, clinical expertise.”

Provided by PLOS

Categories : Cancer DermatologyTags :

Research Finds Protein Behind Radiotherapy-induced Skin Damage

On By ModernMedia

The protein Dickkopf 3 plays a key role in the development of radiation-induced fibroses – and could be a promising target for novel therapies

Picture by Macrovector on Freepik

Radiotherapy is one of the main treatment forms for cancer. Among its most common side effects is skin damage, right up to chronic inflammations and fibroses. At present, such long-term damage can only be treated symptomatically and leads to thickened, painful, or sensitive skin for months to years after the radiation treatment. A team led by LMU immunologist Professor Peter Nelson (LMU University Hospital) and Roger Sandhoff and Peter E. Huber from the German Cancer Research Center (DKFZ) has identified a protein called Dickkopf 3 (DKK3) as a main cause of long-term skin damage after radiotherapy – a decisive step for the development of novel, more targeted therapy options.

The results were published in Signal Transduction and Targeted Therapy.

By investigating mouse models and human cells and tissue samples, the researchers demonstrated that DKK3 is activated after radiotherapy in a certain group of skin cells that are responsible for skin renewal. This activity triggers a chain reaction which promotes inflammations and the formation of scar-like tissue and leads to chronic skin damage. The key findings were driven by the work of LMU students, Li Li and Khuram Shehzad. Their efforts were essential in identifying DKK3 as the critical molecular mediator and in establishing the mechanistic framework presented in the paper. “We also observed similar processes in the kidney,” says Nelson. “This indicates that the activation of DKK3 is a fundamental mechanism that promotes fibrosis in various tissues.”

According to the researchers, these findings underscore that DKK3 represents a promising new treatment target. “Drugs that block DKK3 could one day help prevent or reduce long-term skin damage after radiotherapy and thus improve the quality of life of cancer patients and survivors,” says Nelson. The researchers are currently investigating, moreover, whether this approach could also contribute to the prevention of scar formation in other organs.

Source: Ludwig Maximilian University of Munich

Categories : TransplantsTags :

New Monthly Infusion Could Replace Daily Immunosuppressants for Kidney Transplants

On By ModernMedia

Monthly infusion could replace daily drug regimen with a less toxic treatment that improves renal function.

Photo by Robina Weermeijer on Unsplash

Anew study offers hope that kidney transplant patients could one day have a monthly treatment instead of multiple pills every day. The new treatment also may reduce side effects and increase the lifespan of the donor organ.

Currently, patients who have had a kidney transplant must take a cocktail of pills every day for the rest of their lives. These standard immunosuppressants prevent the immune system from attacking the new organ, but over time may damage kidney function and become less effective.

Plus, standard immunosuppressants are also lead to diabetes, hypertension, high cholesterol, and weight gain that can lead to transplant patients skipping doses, noted the study’s first author Flavio Vincenti, MD, professor of medicine and surgery in the Division of Nephrology at UC San Francisco. Other side effects include fatigue, muscle weakness, sexual dysfunction, hair loss, and sleeplessness.

Patients showed improvement

In the phase 2 pilot study, 23 patients received infusions of belatacept and dazodalibep, proteins that disrupt the immune system’s attack on the new organ but that do not affect non-immune cells the way standard treatment does.

Kidney function improved in all patients who completed the study and was similar for those who experienced organ rejection. No patient experienced rejection due to antibodies produced by the immune system, which is a major cause of transplant failure. Results were published Feb. 3 in the American Journal of Transplantation.

“We would hope to see better medication compliance with the new regimen since it does not involve taking multiple medications every day,” Vincenti said.

Study patients received standard immunosuppressants at first, but these were discontinued by day 28 in favour of the infusions for the remainder of the 48-week study.

Two of the first three patients experienced organ rejection, which was effectively treated and the rejection reversed. Drug frequency and dosing were revised in response for the remaining patients, 13 of whom completed the study. Seven patients withdrew due to acute kidney rejection, side effects, or for unspecified reasons.

The next phase of the study will determine if these early findings are replicated in a large patient pool, said senior author Allan D. Kirk, MD, PhD, professor of surgery at Duke University School of Medicine.

“We hope that most patients can be spared the toxic effects of immunosuppressants, which would be reserved for those with certain high-risk factors,” said Kirk.

Source: University of California San Francisco

Categories : Cardiovascular DiseaseTags :

Men’s Heart Attack Risk Climbs by Mid-30s, Years Before Women

On By ModernMedia

Decades-long US study suggests prevention and screening should start earlier in adulthood

Pexels Photo by Freestocksorg

Men begin developing coronary heart disease – which can lead to heart attacks – years earlier than women, with differences emerging as early as the mid-30s, according to a large, long-term study led by Northwestern Medicine.

The findings, based on more than three decades of patient follow-up, suggest that heart disease prevention and screening should start earlier in adulthood, particularly for men.

“That timing may seem early, but heart disease develops over decades, with early markers detectable in young adulthood,” said study senior author Alexa Freedman, assistant professor of preventive medicine at Northwestern University Feinberg School of Medicine.

“Screening at an earlier age can help identify risk factors sooner, enabling preventive strategies that reduce long-term risk.”

Older studies have consistently shown that men tend to experience heart disease earlier than women. But over the past several decades, risk factors like smoking, high blood pressure and diabetes have become more similar between the sexes. So, it was surprising to find that the gap hasn’t narrowed, Freedman said.

To better understand why sex differences in heart disease persist, Freedman and her colleagues say it’s important to look beyond standard measures such as cholesterol and blood pressure and consider a broader range of biological and social factors.

Tracking heart disease from young adulthood

The study analysed data from the Coronary Artery Risk Development in Young Adults (CARDIA) study, which enrolled more than 5100 Black and white adults ages 18 to 30 in the mid-1980s and followed them through 2020.

Because participants were healthy young adults at enrollment, the scientists were able to pinpoint when cardiovascular disease risk first began to diverge between men and women. Men reached 5% incidence of cardiovascular disease (defined broadly to include heart attack, stroke and heart failure) about seven years earlier than women (50.5 versus 57.5 years).

The difference was driven largely by coronary heart disease. Men reached a 2% incidence of coronary heart disease more than a decade earlier than women, while rates of stroke were similar and differences in heart failure emerged later in life. “This was still a relatively young sample – everyone was under 65 at last follow-up – and stroke and heart failure tend to develop later in life,” Freedman explained.

Beyond traditional risk factors

The scientists examined whether differences in blood pressure, cholesterol, blood sugar, smoking, diet, physical activity and body weight could explain the earlier onset of heart disease in men. While some factors, particularly hypertension, explained part of the gap, overall cardiovascular health did not fully account for the difference, suggesting other biological or social factors may be involved.

A critical age: 35

One of the most striking findings was when the risk gap opened. The scientists found that men and women had similar cardiovascular risk through their early 30s. Around age 35, however, men’s risk began to rise faster and stayed higher through midlife. Heart disease screening and prevention efforts often focus on adults over 40. The new findings suggest that approach may miss an important window.

The authors highlight the relatively new American Heart Association’s PREVENT risk equations, which can predict heart disease starting at age 30, as a promising tool for earlier intervention.

By Ben Schamisso

Source: Northwestern University

Categories : Cancer

More People in the US Are Living 5 Years After Cancer Diagnosis

On By ModernMedia

Northwestern experts explain the new milestone and what it means for patients and the future of research

Source: Unsplash CC0

The American Cancer Society recently released its 2026 statistics report, showing for the first time that 70% of people diagnosed with cancer in the US survive at least five years.

The report highlights especially large survival gains for some of the deadliest cancers, including myeloma, liver cancer and lung cancer, reflecting advances in lifestyle change, early detection, research and targeted therapies.

Northwestern Now spoke to three Northwestern oncologists about what the survival milestone means for patients and the future of research.

For the remaining 30%

“This is a major improvement from the past and the outcome of important cancer research. The challenge is now how we can get the same outcome for the remaining 30% of patients, and how we can do that as soon as possible.”

– Dr. Leonidas Platanias, director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Through decades of sustained investment

“Behind every statistic in this report is a person, a family and a life reshaped by cancer. The progress we’re seeing is real, and it exists because of decades of sustained investment in cancer research that has led to earlier detection, more effective treatments and more personalized care. Critically, as more patients survive cancer, success must be measured not just in years added, but in the quality of those years. Our responsibility now is to keep going. Continued support for research is not optional; it’s the reason these gains are possible, and it’s how we ensure that every patient has a chance at a longer, fuller life.”

– Dr. Mohamed Abazeed, chair and professor of radiation oncology at Northwestern University Feinberg School of Medicine

Considering quality of life

“We need to think about survivorship beyond survival,” Abazeed said. “As more patients live longer with or after cancer, quality of life, functional outcomes, and long-term toxicity become central clinical priorities, not just survival at five years.”

By Ben Schamisso

Source: Northwestern University

Categories : UncategorizedTags :

New Study Reveals that Sex Hormones Reset Circadian Clocks

On By ModernMedia
Photo by Cottonbro on Pexels

The findings may shed new light on disruptions to the circadian clocks during menstruation, pregnancy and menopause

Disruptions to circadian clocks can lead to a wide range of health problems, from sleep disturbances to diabetes and cancer. But there has been no certainty about the identity of the body’s substances that can “shift” these clocks forward or backward and, when altered, potentially cause such disruptions.

A new study from Prof Gad Asher’s lab at the Weizmann Institute of Science, now published in Nature Communications, reveals that sex hormones play a central role in aligning the cellular clocks with one another and with the environment. The research team, led by Drs Gal Manella, Saar Ezagouri and Nityanand Bolshette, showed that female sex hormones – especially progesterone – together with the stress hormone cortisol, have a dramatic effect on the clocks.

It is already known that circadian clocks are affected not only by external signals such as sunlight but also by signals carried through the bloodstream. Until now, however, these blood-borne signals had not been fully mapped, and there was no certainty about the component within the clock that serves as their “point of entry.” The reason: Researchers lacked a precise method for tracking the clock’s response to different signals over a full 24-hour cycle.

In recent years, Prof Asher’s lab – an international leader in studying the molecular mechanisms of circadian clocks – developed an ingenious method that uses an array of human cells each representing a different “time of day.” It resembles a wall lined with clocks showing the current time in major cities around the world. The new approach enabled the researchers, for the first time and with unprecedented precision, to map how the cellular clocks are synchronized by blood-borne signals.

In addition to uncovering the influence of sex hormones, the study revealed that the clock component receiving these signals is the protein Cry2, rather than Per2, as previously believed.

The “ticking” of a circadian clock inside a human cell over the course of 24 hours. A fluorescent marker allows scientists to tell “what time it is” at any given moment

“The levels of sex hormones change throughout life – during menstrual cycles, pregnancy, hormone therapy, contraceptive use and various disease states. These conditions are also known to be associated with disturbances to circadian clocks,” Asher notes. “Our new findings suggest that these disturbances are linked to interactions between sex hormones and the mechanisms that synchronize circadian clocks.”

Source: Weizmann Institute of Science